Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 151
Inquire Before Buying

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 11, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H5N1 Subtype Infections - Overview
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
Akshaya Bio Inc
Altimmune Inc
Antigen Express Inc
Aphios Corp
BiondVax Pharmaceuticals Ltd
CEL-SCI Corp
Cocrystal Pharma Inc
Curevac AG
Gemmus Pharma Inc
GlaxoSmithKline Plc
Hemispherx Biopharma Inc
iBio Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Lakewood-Amedex Inc
Medicago Inc
Medigen Vaccine Biologics Corp
Microbiotix Inc
NanoBio Corp
Nanotherapeutics Inc
NanoViricides Inc
OPKO Health Inc
PaxVax Inc
PeptiDream Inc
Shionogi & Co Ltd
Takeda Pharmaceutical Company Ltd
TechnoVax Inc
Vaxart Inc
Vaxine Pty Ltd
Visterra Inc
Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
A-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AE-AI vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alferon LDO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-0205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beraprost sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-42344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHOS-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GP-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GP-1681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GREFLU/VIE - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HAI-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-36.6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influ-nRNA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] (split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H5N1 + A/H1N1] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lalistat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2329 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2546 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MV-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Influenza Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pimodivir hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNSIA-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNSIA-49 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXVX-0103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-033188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Sirtuin for Influenza - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3400X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VH-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant
Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine
Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza
Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.
Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine
Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line
Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting
Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company's Universal Flu Vaccine
Jan 21, 2014: BiondVax's universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8
Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO
Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Hemispherx Biopharma Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by iBio Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoBio Corp, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Nanotherapeutics Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by PaxVax Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Pipeline by Visterra Inc, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..3), H2 2017
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
  • United States Tigecycline Market Report 2017
    Published: 22-Nov-2017        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Tige......
  • Global Tigecycline Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Tigecycline for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - South......
  • Global and Regional Cephalosporin Market Research Report 2017
    Published: 15-Nov-2017        Price: US 3500 Onwards        Pages: 180
    Summary Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium" Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - First Generation - Second Generation......
  • United States Cefprozil Market Report 2017
    Published: 15-Nov-2017        Price: US 3800 Onwards        Pages: 114
    In this report, the United States Cefprozil market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Cefpro......
  • Q Fever - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 36
    Q Fever - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Q Fever - Pipeline Review, H2 2017, provides an overview of the Q Fever (Infectious Disease) pipeline landscape. Q fever, also called query fever, is a bacterial infection caused by the bacteria Coxiella burnetii. Common symptoms of Q fever include high fever, cough, headache, diarrhea, nausea, abdominal pain, jaundice and muscl......
  • Escherichia coli Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 171
    Escherichia coli Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into cont......
  • Tularaemia - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 72
    Tularaemia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape. Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conju......
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 84
    Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape. Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomyci......
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 369
    Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape. MRSA infections that are acquired by persons who have n......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs